ANTX

AN2 Therapeutics, Inc. ANTX

Net profit

EBITDA

P/E Ratio

Capitalization

Performance

Periode ANTX QTTB PSTV PLUR BOLD NXTC IBIO ITRM SABS INTS
6M 2.73 % 80.00 % 186.42 % -31.21 % 22.12 % 93.55 % 110.00 % -60.97 % 122.47 % 31.63 %
YTD -18.71 % -16.52 % -50.85 % -31.52 % -53.48 % 6.59 % -21.90 % -78.74 % 6.74 % -76.01 %
1Y -13.74 % -7.99 % -42.00 % -29.40 % -49.20 % -1.59 % -21.25 % -76.70 % 18.56 % -78.02 %
3Y -88.47 % -87.69 % -87.53 % -61.79 % 12 699 900.00 % -32.11 % -76.38 % -61.01 % -51.12 % -92.95 %
5Y -92.66 % -98.70 % -98.10 % -94.04 % 12 699 900.00 % -91.71 % -99.67 % -97.10 % -96.10 % -92.95 %
10Y -92.66 % -99.14 % -100.00 % -96.86 % 12 699 900.00 % -95.60 % -99.94 % -99.80 % -96.10 % -92.95 %
From the beginning -92.66 % -99.14 % -100.00 % -99.99 % 12 699 900.00 % -95.60 % -99.96 % -99.80 % -96.10 % -92.95 %

Dividend

AN2 Therapeutics, Inc.